Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 single-arm study of JS001 in MSI-H advanced or recurrent colorectal cancer
ChiCTR1900022491Phase 2Not yet recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Jun 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of toripalimab in colorectal cancer (CRC), sponsored by Zhongshan Hospital, Fudan University. Primary endpoint: Objective response rate. Planned start Jun 2019; status: not yet recruiting.
02
Drugs
toripalimab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR1900022491.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900022491.